<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEB10C4F-5479-4941-B0B4-0CAD06381596"><gtr:id>BEB10C4F-5479-4941-B0B4-0CAD06381596</gtr:id><gtr:name>Veterinary Laboratories Agency</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEB10C4F-5479-4941-B0B4-0CAD06381596"><gtr:id>BEB10C4F-5479-4941-B0B4-0CAD06381596</gtr:id><gtr:name>Veterinary Laboratories Agency</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D5568E1D-EFE4-448E-821B-3B135E754B5D"><gtr:id>D5568E1D-EFE4-448E-821B-3B135E754B5D</gtr:id><gtr:firstName>Yasuhiro</gtr:firstName><gtr:surname>Takeuchi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7E3281C6-612C-45FF-9983-C1A56933E82A"><gtr:id>7E3281C6-612C-45FF-9983-C1A56933E82A</gtr:id><gtr:firstName>Marlen</gtr:firstName><gtr:otherNames>Maria</gtr:otherNames><gtr:surname>Aasa-Chapman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2"><gtr:id>3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Weiss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801176"><gtr:id>69B66C9F-5586-4F71-B204-E021BF283B93</gtr:id><gtr:title>Humoral immunity to Human Immunodeficiency Virus (HIV)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801176</gtr:grantReference><gtr:abstractText>Great advances have been made in the detection and treatment of HIV and AIDS, but a vaccine to prevent HIV infection, one that works and is safe, still lies many years away. Our research aims to bring this day forward: First, to gain a better groundwork for the humoral arm of the immune response to HIV, we shall determine recognition signatures on the outer envelope of HIV which will induce antibodies that protect against HIV infection. This will be done with antibody fragments cloned from blood samples of llamas because they have particular advantages for analytical work. Second, we will study antibodies that may have the opposite effect, enhancing infection rather than protecting against it. Blood samples taken from human volunteers who have given a test vaccine will be analysed to see if the balance between protective antibodies and infection-enhancing antibodies can be shifted so that protection from HIV becomes dominant. Protective antibody fragments will also be explored for future use as possible microbicides that can be introduced into the vagina to reduce the risk of infection during and after sexual intercourse.</gtr:abstractText><gtr:technicalSummary>This research proposal comprises two related projects: [A] We shall analyse neutralising epitopes on the HIV envelope that block attachment or entry into target cells. These will be studied with single-chain antibody fragments (VHH) derived from llamas which have been immunised with recombinant gp120 or gp140 of subtype A and C strains of HIV-1. In particular, we shall focus on VHH that bind in or around the CD4-recognition pocket on gp120 and thereby neutralise infection by blocking the docking of HIV to CD4+ cells. All strains of HIV-1, HIV-2 and SIV bind to CD4 and the VHH will enable us to determine the variability and constraints of the CD4-binding site. Some of the VHH have potential utility as microbicides and as tools to analyse envelope-based immunogens as components of candidate vaccines designed to elicit humoral immunity. [B] We shall elucidate the role of innate and acquired humoral immunity by non-neutralising antibodies that bind to the HIV-1 envelope. In conjunction with Complement these antibodies can induce inactivation of HIV and may contribute to clearance of primary viraemia during seroconversion. However, for cells expressing a Complement receptor (CR2), we have observed massive enhancement of infection including enhancement mediated by antibodies in sera of volunteer vaccinees immunized with gp120. The mechanism of action and the epitopes targeted by Complement-inactivating and enhancing, non-neutralising anti-Env antibodies, will be analysed using clinical serum samples and human MAbs. Both CR-transfected cell lines and HIV target cells that naturally express CR will be used to dissect the balance between Complement-mediated HIV inactivation and Complement-mediated enhancement.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>800048</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Veterinary Medicine Glasgow</gtr:department><gtr:description>U Glasgow Vet School</gtr:description><gtr:id>E19E470E-D81A-4968-9934-376C2370A92B</gtr:id><gtr:impact>Academic paper</gtr:impact><gtr:outcomeId>kRx7uxCCHtN-1</gtr:outcomeId><gtr:partnerContribution>serosurveillance</gtr:partnerContribution><gtr:piContribution>Neutralisation studies of rabies virus</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Veterinary Laboratories Agency</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DEFRA Animal Health Veterinary Laboratories Agency (AHVLA)</gtr:description><gtr:id>E3F91E5E-9886-4E02-9092-A74F3AF02507</gtr:id><gtr:impact>The complementation of the expertise at UCL supported by this grant and that of virologists and epidemiologists at the VLA have resulted in useful outputs and outcomes that would not have been possible either organisation acting alone. 19925950 19787037</gtr:impact><gtr:outcomeId>64C8C1478BA-1</gtr:outcomeId><gtr:partnerContribution>Each organisation has paid for the aspects of the research conducted within its own laboratories. The intellectual and practical contributions have been synergistic rather than additive.</gtr:partnerContribution><gtr:piContribution>Our rabies and lyssavirus research is conducted in close collaboration with colleagues at the VLA.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>U Utrecht</gtr:description><gtr:id>922446AD-D269-4694-B97A-B737512C0D1C</gtr:id><gtr:impact>Several academic papers</gtr:impact><gtr:outcomeId>ivQtavXNRK8-1</gtr:outcomeId><gtr:partnerContribution>developed llama antibody libraries</gtr:partnerContribution><gtr:piContribution>Llama VHH neutralising antibodies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Film showing</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>1BF88C30-A6AB-4F71-AABD-6414469EFD6C</gtr:id><gtr:impact>66 science and medicine journalists from the BBC and newspapers and general scinetific journals

Press commentaries</gtr:impact><gtr:outcomeId>GUw6L12q3C2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Courtauld Lecture Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F8DACB7-DE69-423E-9CA9-B5146C985049</gtr:id><gtr:impact>There was extended discussion, a URL presentation and a printed version of the lecture in press.

Teachers reported great enthusiasm from pupils about understanding infectious disease.</gtr:impact><gtr:outcomeId>CSE3zNweMoo</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Congress of Science Journalists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>B61CF7B9-CFDA-42FF-8CB2-AEBAAFB24D27</gtr:id><gtr:impact>I gave an invited talk on progress and challenges of HIV vaccines.

I receive and respond to enquiries from journalists in several countries requesting background information in this field.</gtr:impact><gtr:outcomeId>FFE5ECA3A2D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Israeli President's Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>B52FAC57-1FFF-4395-84DD-5C5ED513A739</gtr:id><gtr:impact>400 international public servants and a few politicians

Several emails asking for popular articles about pandemics</gtr:impact><gtr:outcomeId>VCSL9Js6NVF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Combined Highly Active Anti-Retroviral Microbicides</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>FFFD6552-537D-4AAF-9839-9D2A269411F2</gtr:id><gtr:outcomeId>F40B25A45FB0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC EP/G062064/1 Multi-Marker Nanosensors for HIV</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G062064/1</gtr:fundingRef><gtr:id>CD6FC429-D0B4-45B8-B737-F24E5EB093E9</gtr:id><gtr:outcomeId>899A4FA5AFE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of llama VHH to define paratopes of the CD4 binding site on gp120 of HIV-1.</gtr:description><gtr:grantRef>G0801176</gtr:grantRef><gtr:id>44C882A6-07D5-4349-81E7-937C8736F596</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>bkomcDwtqXA</gtr:outcomeId><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Broadly neutralizing VHH against HIV-1</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Global HIV Vaccine Enterprise</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>54ADEAA6-7FBB-4F07-8836-1B87F925AEDC</gtr:id><gtr:impact>Too early to measure.</gtr:impact><gtr:outcomeId>F6A7963ED31</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International AIDS Vaccine Initiative (IAVI)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E996C675-AB56-4016-9557-7431D818FAA7</gtr:id><gtr:impact>The PI on this MRC grant is a member of the IAVI Scientific Advisory Committee which has an impact on international health policy.</gtr:impact><gtr:outcomeId>1294F1BA512</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NIHR-MRC Public Health Infections Research Strategy Workshop</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>C6FD9854-349C-4A64-A1EB-D388AF25EB25</gtr:id><gtr:impact>Too recent to measure impact.</gtr:impact><gtr:outcomeId>2FA72100F19</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Select Committee of Parlament</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D8A52E23-1059-400D-9F2D-28F4D3BC5892</gtr:id><gtr:impact>The DoH is supposed to heed Select Committees.</gtr:impact><gtr:outcomeId>9D25E115801</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Royal Society/AcMedSci Advisory Committee on Pandemic Influenza</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>4BF25775-985C-4205-865F-2287E3FF8E72</gtr:id><gtr:impact>Reports are sent to DoH</gtr:impact><gtr:outcomeId>nJH1SyZDxV5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The llama VHH are single chain antibody fragments that have the binding capacity and specificity of antibodies.</gtr:description><gtr:id>41B28D5B-5A70-4972-B4D2-9371041F0F47</gtr:id><gtr:impact>They were added to international repositories from which other researchers could gain access to these reagents. They also form part of international panels of HIV neutralizing antibodies used for research and biological standardization.</gtr:impact><gtr:outcomeId>536BB97EB16</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Llama antibody (VHH) fragments</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>401A3AFA-8381-4141-81C1-7D9D20CDB723</gtr:id><gtr:title>Llama antibody fragments have good potential for application as HIV type 1 topical microbicides.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/914b00ee1f3d1602d258c46d43b6c0b9"><gtr:id>914b00ee1f3d1602d258c46d43b6c0b9</gtr:id><gtr:otherNames>Gorlani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_15024_24_21864083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>908825B7-9011-4404-936E-3F57CC58EB38</gtr:id><gtr:title>Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8f24d249ab4748fb2a46da8d1fcbbe9"><gtr:id>b8f24d249ab4748fb2a46da8d1fcbbe9</gtr:id><gtr:otherNames>Ramsuran V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>kpq9sZCgd63</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4FDEFBC-DB88-48F2-93BE-4B1A77B3B6B8</gtr:id><gtr:title>Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654a6d10a06f182dd8f0d98e126c3340"><gtr:id>654a6d10a06f182dd8f0d98e126c3340</gtr:id><gtr:otherNames>Wright E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>pm_15024_24_20951400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF49FFC8-BEBA-4B95-B524-1FF9C045B6C9</gtr:id><gtr:title>Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d2f75f418faedb6fd9153213e83fa04"><gtr:id>3d2f75f418faedb6fd9153213e83fa04</gtr:id><gtr:otherNames>Willey S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>khEni5p1uHj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C531853B-9395-4170-B6A9-B15E9C79D242</gtr:id><gtr:title>Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>tDrytTbsATC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7457699E-1CA7-43BA-810D-9AAA779E95DF</gtr:id><gtr:title>Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8872400fd9dff62c063a79bbf9476b2"><gtr:id>d8872400fd9dff62c063a79bbf9476b2</gtr:id><gtr:otherNames>Hultberg A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>kPykoQH63Fe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78BC4B16-65C3-4E45-8343-ABE3962BA4C1</gtr:id><gtr:title>Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654a6d10a06f182dd8f0d98e126c3340"><gtr:id>654a6d10a06f182dd8f0d98e126c3340</gtr:id><gtr:otherNames>Wright E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>36916917_F36916917_F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>931C51A8-E8A4-4BE8-9C9B-812D5B3B361A</gtr:id><gtr:title>Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa0eb6704756828dc986d88fcc4bada"><gtr:id>3fa0eb6704756828dc986d88fcc4bada</gtr:id><gtr:otherNames>Strokappe N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15024_24_22438910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4753A65-3B61-4BD3-9BD4-4247DB864865</gtr:id><gtr:title>A robust lentiviral pseudotype neutralisation assay for in-field serosurveillance of rabies and lyssaviruses in Africa.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654a6d10a06f182dd8f0d98e126c3340"><gtr:id>654a6d10a06f182dd8f0d98e126c3340</gtr:id><gtr:otherNames>Wright E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>8D283FBA201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A39D016B-875A-4ED4-8130-A7938556301A</gtr:id><gtr:title>Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d296ae9ff9dc398afaae0bc625303d4"><gtr:id>6d296ae9ff9dc398afaae0bc625303d4</gtr:id><gtr:otherNames>Iba?ez LI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>bsuUmMjwUtm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC081D28-C31A-4776-AE2D-B84013FABC3A</gtr:id><gtr:title>Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c192d8ff6e58b9d307bb0cab17640e26"><gtr:id>c192d8ff6e58b9d307bb0cab17640e26</gtr:id><gtr:otherNames>Koh WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>kXmE8VNVNwH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>607056BD-89B2-48A9-9916-1656E92AAA1F</gtr:id><gtr:title>Henipavirus neutralising antibodies in an isolated island population of African fruit bats.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c01a07c6677636a7dfab3355a6cfaac"><gtr:id>8c01a07c6677636a7dfab3355a6cfaac</gtr:id><gtr:otherNames>Peel AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15024_24_22253928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19B21FC-FF5B-42A6-A625-BCA58A8350E1</gtr:id><gtr:title>Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c192d8ff6e58b9d307bb0cab17640e26"><gtr:id>c192d8ff6e58b9d307bb0cab17640e26</gtr:id><gtr:otherNames>Koh WW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>txrc5vcrvCF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B59710D-62F1-4126-AB53-660A45B2E2E7</gtr:id><gtr:title>Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/327816a670b79f4ebb4116f86acfabff"><gtr:id>327816a670b79f4ebb4116f86acfabff</gtr:id><gtr:otherNames>Fooks AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>A8B10008AB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5B9225B-9807-4A30-B80B-D565FFCA78C8</gtr:id><gtr:title>The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18a5c3495d9f3ba26d058ad8932d0e6d"><gtr:id>18a5c3495d9f3ba26d058ad8932d0e6d</gtr:id><gtr:otherNames>Kulkarni H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>31EC7B77A8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C756CAA-E488-4B71-BA9D-082B04B1E4E4</gtr:id><gtr:title>Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7219e699c28c45d6e339476809f7f10"><gtr:id>c7219e699c28c45d6e339476809f7f10</gtr:id><gtr:otherNames>de Silva TI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15024_24_22072758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>257083F4-F5BD-436D-A7C3-561CFA248DC8</gtr:id><gtr:title>Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0143de37e46d8a91c66f83dee9425f2"><gtr:id>f0143de37e46d8a91c66f83dee9425f2</gtr:id><gtr:otherNames>McCoy LE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>pm_15024_24_22641382</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEC5C910-A3AC-408F-B1ED-F5207CC8049B</gtr:id><gtr:title>On HIV diversity.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ea19b600a14491beff8e183278be0a4"><gtr:id>4ea19b600a14491beff8e183278be0a4</gtr:id><gtr:otherNames>Ndung'u T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15024_24_22706010</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801176</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>